Article

Large Scale In-House Point-of-Care Manufacturing of Clinical Grade Autologous Anti-CD19 CAR T Cells in Saudi Arabia

2024-06-12

Abstract excerpt

<h4>ABSTRACT</h4> Chimeric Antigen Receptor T (CAR T) cell therapy targeting the CD19 antigen represents a significant advancement in the treatment of various subtypes of CD19-expressing hematologic malignancies. Nevertheless, the current commercial CAR T manufacturing process is intricate, time-consuming, and costly, involving a supply chain that initiates at the treating center with mononuclear cell apheresis, f...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 81ec464f-d5ab-5ba3-adc6-25404c7d4737
DOI: 10.1101/2024.06.11.24308741

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Large Scale In-House Point-of-Care Manufacturing of Clinical Grade Autologous Anti-CD19 CAR T Cells in Saudi ArabiaDOI 10.1101/2024.06.11.24308741Read

Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma.Semantic proximity Read

Development of Ingenui-T, a Novel Vein-to-Vein Solution for Rapid Autologous CAR T-Cell Manufacturing Starting From Whole Blood, for the Treatment of Autoimmune DiseasesSemantic proximity Read

Development of a 3-day manufacturing method to generate CD19-CD20-CD22 trispecific CAR T-cells from whole blood.Semantic proximity Read

Global Manufacturing of CAR T Cell TherapySemantic proximity Read

Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospectsSemantic proximity Read

Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use.Semantic proximity Read

Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignanciesSemantic proximity Read

Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-T <sub>SCM</sub> cells using <i>qCART</i> , the <i>Quantum pBac</i> -based CAR-T systemSemantic proximity Read

A closed, autologous bioprocess optimized for TCR-T cell therapiesSemantic proximity Read

Automated, scaled, transposon-based production of CAR T cellsSemantic proximity Read

Media evaluation for production and expansion of anti-CD19 chimeric antigen receptor T cells.Semantic proximity Read

Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapiesSemantic proximity Read